Degenerative Nerve Diseases
Also known as: Neurodegenerative diseases
Methodology & AI Transparency ⓘ
Degenerative Nerve Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Degenerative nerve diseases affect many of your body's activities, such as balance, movement, talking, breathing, and heart function.
- 2 Real-world patient consensus: Diagnostic registry G35.3: Degenerative Nerve Diseases is managed within Brain & Neurology (aka Neurodegenerative diseases).
- 3 Typical cash cost range: Differential triage of Degenerative Nerve Diseases (G35.3) utilizes neurorehabilitation tracking [Degenerative Nerve Diseases G35.3].
- 4 Top reported side effects / signs: Objective lab/clinical target for Degenerative Nerve Diseases: Serum Vitamin B12 in Degenerative Nerve Diseases (G35.3: & Methylmalonic Acid) (B12 > 500 pg/mL; MMA < 240 nmol/L (G35.3)) and Carotid Duplex / in Degenerative Nerve Diseases (G35.3: Cerebral Perfusion).
Ask our AI Specialists anything about Degenerative Nerve Diseases
What Is Degenerative Nerve Diseases?
Degenerative nerve diseases affect many of your body's activities, such as balance, movement, talking, breathing, and heart function. Many of these diseases are genetic. Sometimes the cause is a medical condition such as alcoholism, a tumor, or a stroke. Other causes may include toxins, chemicals, and viruses. Sometimes the cause is unknown. Degenerative nerve diseases include: Alzheimer's disease Amyotrophic lateral sclerosis Friedreich ataxia Huntington's disease Lewy body disease Parkinson's disease Spinal muscular atrophy Degenerative nerve diseases can be serious or life-threatening. It depends on the type. Most of them have no cure.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Degenerative Nerve Diseases (ICD-10 G35.3) is driven by blood-brain barrier neuroinflammation [Degenerative Nerve Diseases G35.3]; Cross-referenced with NIH MeSH (Neurodegenerative Diseases), specialists in Neurology, Stroke & Movement Disorders monitor Carotid Duplex / in Degenerative Nerve Diseases (G35.3: Cerebral Perfusion) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Alzheimer's disease
- • Amyotrophic lateral sclerosis
- • Presentation of Degenerative Nerve Diseases (G35.3): episodic vertigo, imbalance, in Degenerative Nerve Diseases (G35.3: coordination drift, or)
- • Secondary Degenerative Nerve Diseases clinical sign: numbness, paresthesia, or in Degenerative Nerve Diseases (G35.3: visual field/speech changes)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Degenerative Nerve Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G35.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Degenerative Nerve Diseases (G35.3: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G35.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Degenerative Nerve Diseases (G35.3: Cerebral Perfusion) | No hemodynamically significant stenosis (G35.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Degenerative Nerve Diseases (G35.3: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G35.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Degenerative Nerve Diseases
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Oxervate (Cenegermin-Bkbj) Oxervate • RxCUI RXN-B71981001 | Recombinant Human Nerve Growth Factor | 84% | $3.5600 | $ 264.82 /mo |
| Fluorodopa F18 Fluorodopa F18 Generic • RxCUI RXN-13267346-1787 | FDA Prescription Therapeutic Agent | 86% | $0.5900 | $ 32.39 /mo |
| Avance Nerve Graft (Processed Nerve Allograft) Avance Nerve Graft • RxCUI 2749427 | FDA Prescription Therapeutic Agent | 88% | $2.5900 | $ 194.98 /mo |
| Processed Nerve Allograft Avance Nerve Graft • RxCUI 2749421 | FDA Prescription Therapeutic Agent | 84% | $1.9500 | $ 87.48 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Degenerative Nerve Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pimavanserin safety in adult and older adults patients with neuropsychiatric: What a 595-Participant Study Found The mean. Journal of Alzheimer's disease : JAD • 2025-07-15 • Phase III Randomized Trial | N = 595 | 93/100 | PMID 40518812 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of safinamide according to gender in Chinese parkinsonian Safinamide was shown to improve PD symptoms and quality of life in both male and female Chinese patients. Scientific reports • 2023-11-23 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37996493 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety Profile of Pimavanserin Therapy in older adults Patients with Pimavanserin was well tolerated and not associated with motor or cognitive impairment. Journal of Alzheimer's disease : JAD • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38427485 ↗ |
| Can This Approach Help? Inside the Latest Research on Evolution of atrophied T2 lesion volume in primary-progressive multiple OCR showed a significant effect of reducing the accumulation of aT2-LV in PPMS in the DBP period and was related to CDP-EDSS in OLE only in the PBO arm. Journal of neurology, neurosurgery, and psychiatry • 2024-05-14 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38071574 ↗ |
| New Insights on Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative: What a 283-Participant Study Found The odds of postoperative C5 palsy are significantly higher after posterior decompression compared to anterior decompression for DCM. Spine • 2024-10-15 • Phase III Randomized Trial | N = 283 | 87/100 | PMID 38616732 ↗ |
Degenerative Nerve Diseases Patient Community & “People Like Me” Threads
Filter Degenerative Nerve Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.